|
UBE2CBP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.40500000000987E-06 |
| Normal-vs-Stage3 |
3.58602036953926E-14 |
| Normal-vs-Stage4 |
1.33369981725195E-11 |
| Stage1-vs-Stage2 |
3.629900E-02 |
| Stage1-vs-Stage3 |
2.677000E-01 |
| Stage1-vs-Stage4 |
2.957200E-01 |
| Stage2-vs-Stage3 |
1.669910E-02 |
| Stage2-vs-Stage4 |
2.092400E-02 |
| Stage3-vs-Stage4 |
8.821800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.550800E-04 |
| Normal-vs-Asian |
5.94390092700792E-11 |
| Caucasian-vs-AfricanAmerican |
1.399400E-01 |
| Caucasian-vs-Asian |
8.127000E-01 |
| AfricanAmerican-vs-Asian |
1.116610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.62012633811537E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.372800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
9.10382880192628E-15 |
| Normal-vs-Age(61-80Yrs) |
9.52671275200601E-12 |
| Normal-vs-Age(81-100Yrs) |
7.402200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.402800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.659600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.769200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.121600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.108600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.169000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.365300E-04 |
| Classical-VS-Follicular |
2.58850000001143E-06 |
| Classical-VS-Other |
1.684780E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
1.80439996277926E-09 |
| Tall-VS-Other |
1.043590E-03 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
6.589200E-01 |
| Follicular-VS-Normal |
7.68630000000936E-05 |
| Other-VS-Normal |
1.431860E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.8746783559418E-14 |
| Normal-vs-N1 |
1.02928776612998E-12 |
| N0-vs-N1 |
2.490400E-02 |
|
|
